Navigation Links
DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference
Date:9/3/2009

ical trial of DOR201 in radiation enteritis in the second half of 2009. orBec(R) is also currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. Additionally, DOR has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin and botulinum toxin. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.

For further information regarding DOR BioPharma, Inc., please visit the Company's website at www.dorbiopharma.com.

This press release contains forward-looking statements that reflect DOR BioPharma, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including DOR201, orBec(R) and LPM(TM), particularly in light of the significant uncertainty inherent in developing vacci
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
2. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
5. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
6. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
7. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
8. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
9. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...EW YORK, Nov. 19 NeoStem... has sent the following letter to its shareholders... 30, 2009, of China Biopharmaceuticals Holdings, I...ny based in the People,s Republic of China. The me...uzhou Eyre Pharmaceutical Co. Ltd., CHBP,s primary...
(Date:11/19/2009)...ONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutic...ient in a randomized Phase 2B study of AEG35156, a...opment for multiple oncology indications. ,, Th...2 Study of the X-Linked Inhibitor of Apoptosis (XI...igh-dose Cytarabine and Idarubicin in AML Followin...
(Date:11/19/2009)..., VIENNA, Austria, November 19 /PRNewswire/ -...ogram on one product candidate at an unexpectedly ...AD02 is planned to enter into,Phase II clinical tr...mediately follows the completion of two Phase I tr...y based its fast decision on the first interim,ana...
(Date:11/18/2009)...N, Ill. Imagine a polka-dotted postage stamp that...mply by changing colors. , As reported in the Se...nneth Suslick and his team at the University of Il...eneral detection of toxic industrial chemicals (TI...s by visualizing odors. This sensor array could b...
Breaking Biology Technology:NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3
... JOSE, Calif., Jan. 21 VNUS(R) Medical,Technologi...edical devices,for the minimally invasive treatmen...hat it plans to report its financial results for t...he close of market on,February 7., VNUS plans to ...p.m. PT,/ 5:00 p.m. ET on February 7. This call wi...
...fee, tea, soda and hot chocolate present risk, OA...ne,during pregnancy -- whether from coffee, tea, c...ased risk of miscarriage, according a new study,by...tudy controlled, for,the first time, pregnancy-rel...rsion that tended to interfere with the determinat...
... DIEGO, Jan. 18 The San Diego Consortium for,Rege...has received the,highest score in three of four ca...tive Medicine (CIRM) on Part I of the Major Facili...ch was submitted last October, earned scores of,99...cal research, 94 for,preclinical development and 9...
Other Biology Technology:VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7 2Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 3Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 4SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application 2SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application 3
(Date:11/22/2009)...009 Agios Pharmaceuticals today announced that it... that the mutated IDH1 gene has a novel enzyme act...cogene. This breakthrough discovery shows that the...roxyglutarate (2HG), which may contribute to the f... most common type of brain cancers. This discovery...
(Date:11/20/2009)...in the November 2009 issue of the journal GENETIC...w a family of genes (1-aminocyclopropane-1-carboxy...roduction of ethylene. This gas affects many aspec... the foundation for future genetic manipulation th...rvive and thrive in difficult terrain, increase yi...
(Date:11/20/2009)...ribute their abstracts to the World Congress on Os...obal meeting devoted to all aspects of osteoporosi...e Congress will be held in Florence, Italy from Ma... submitted online at http://www.iofwco-ecceo10.or...0. , IOF and ESCEO are pleased to announce that ...
Breaking Biology News(10 mins):Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 3Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 4It's a gas: New discovery may lead to heartier, high-yielding plants 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3FDA Study 3A Lead Levels in Lipstick Much Higher Than Previously Reported 55893 1FDA Study 3A Lead Levels in Lipstick Much Higher Than Previously Reported 55893 2St Lukes Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment 55891 1St Lukes Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment 55891 2St Lukes Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment 55891 3Dermal Filler Procedures Jump 30 25 at Center For Cosmetic and Plastic Surgery 55889 1Dermal Filler Procedures Jump 30 25 at Center For Cosmetic and Plastic Surgery 55889 2Dermal Filler Procedures Jump 30 25 at Center For Cosmetic and Plastic Surgery 55889 3
...OLD SPRING HARBOR, N.Y. (Tues., March 3, 2009) T...roteins in cells are featured in the March issue o...s.org/TOCs/toc3_09.dtl ). Thomas J. Wandless and ...ess.stanford.edu/ ) provide detailed instructions ...ls Using Small Molecules." This technique provides...
...th the growing volume of online scientific data, a...rch that will have a direct impact on scientists a...ation services, Faculty of 1000 Biology and Facult...o complement their award-winning service. The new ...g scientific journals as most of their content has...
...ld Spring Harbor, N.Y. Most of the DNA in the nuc...ut only a small fraction of these RNA molecules se...ins. Of the remaining RNAs, known as "non-coding" ...wn: they inhibit the activity of genes or modify t...ithin cells. What the rest of them do within cells...
Other Biology News:Protein function and chromatin structure methods featured in Cold Spring Harbor Protocols 2World's experts identify the hottest trends in biology and medicine 2CSHL researchers pinpoint structure-building role for 2 non-coding RNAs 2CSHL researchers pinpoint structure-building role for 2 non-coding RNAs 3
...PBL's bioassays for interferons are cytopathic eff...iral assays. Sample types include; tissue culture...formulations. In these assays, one unit is define...liter to reduce the cytopathic effect of viral inf...
Hybridization module,Hypro100 from Thermo Scientific
...PBL's bioassays for interferons are cytopathic eff...iral assays. Sample types include; tissue culture...formulations. In these assays, one unit is define...liter to reduce the cytopathic effect of viral inf...
T4 DNA Polymerase from New England Biolabs
Biology Products: